Neural transcriptomic signature of chronic wasting disease in white-tailed deer

Eóin O’Hara1,2, Allen Herbst1, Arun Kommadath3, Judd M. Aiken1, Debbie McKenzie4, Negin Goodarzi5, Pamela Skinner5 and Paul Stothard1*

Abstract

Background: The increasing prevalence and expanding geographical range of the chronic wasting disease (CWD) panzootic in cervids is threatening human, animal, environmental and economic health. The pathogenesis of CWD in cervids is, however, not well understood. We used RNA sequencing (RNA-seq) to compare the brain transcriptome from white-tailed deer (WTD; Odocoileus virginianus) clinically affected with CWD (n = 3) to WTD that tested negative (n = 8) for CWD. In addition, one preclinical CWD+ brain sample was analyzed by RNA-seq.

Results: We found 255 genes that were significantly deregulated by CWD, 197 of which were upregulated. There was a high degree of overlap in differentially expressed genes (DEGs) identified when using either/both the reference genome assembly of WTD for mapping sequenced reads to or the better characterized genome assembly of a closely related model species, Bos taurus. Quantitative PCR of a subset of the DEGs confirmed the RNA-seq data. Gene ontology term enrichment analysis found a majority of genes involved in immune activation, consistent with the neuroinflammatory pathogenesis of prion diseases. A metagenomic analysis of the RNA-seq data was conducted to look for the presence of spiroplasma and other bacteria in CWD infected deer brain tissue.

Conclusions: The gene expression changes identified highlight the role of innate immunity in prion infection, potential disease associated biomarkers and potential targets for therapeutic agents. An association between CWD and spiroplasma infection was not found.

Introduction

Chronic wasting disease (CWD) is a naturally occurring, universally fatal prion disease or transmissible spongiform encephalopathy (TSE) of cervids (e.g. deer, moose, elk) [1]. First described in captive Colorado mule deer in 1967, the disease is now found in farmed and free-ranging cervid populations across North America, with additional cases documented in Scandinavia and South Korea [2]. The prevalence of CWD can be very high, above 50% in some free-ranging populations and 90% in some captive herds. Surveillance and management of captive cervids is effective in reducing disease prevalence [2]. Continued expansion of endemic areas may have significant implications for the long-term sustainability of cervid populations in North America [3].

TSEs are progressive neurodegenerative disorders, characterised by the aggregation of misfolded prion proteins in the neural tissues of infected hosts [4]. The infectious prion, PrP\textsubscript{CWD}, converts the cellular prion protein, PrP\textsubscript{C}, into PrP\textsubscript{CWD}. Migration of the infectious prions to the nervous system results in full brain involvement and clinical disease and involves widespread deposition of PrP\textsubscript{CWD} in numerous brain areas, but especially the obex, superior colliculus, hypothalamus, septal nucleus of the basal ganglia and cerebellum [5]. The accumulation of PrP\textsubscript{CWD} leads to gliosis and astrogliosis, hallmark
neuronal vacuolation, progressive degeneration, and ultimately, death of the host [6].

Increasing our understanding of the key pathways affected by the accumulation of PrP<sub>CWD</sub> may provide targets for early disease diagnosis or transmission and enable approaches to mitigate the disease. A previous study of neural transcript expression profiles in BSE-infected macaques indicated the dysregulation of genes involved in oxygen and lipid transport, and in innate immune processes [7]. Basu and colleagues similarly reported that CWD-infected elk had altered expression of immune-regulatory gene transcripts in the brain [8]. A recent study in deer utilized high-throughput sequencing to examine the impact of CWD on transcription profiles in liver and lymph node tissues [9], but to the best of our knowledge, no study has used RNA sequencing (RNA-seq) to examine neural gene expression profiles in CWD-infected cervids. In the present study, we use RNA-seq of brain tissue collected from CWD-positive and CWD-negative white-tailed deer (WT; <em>Odocoileus virginianus</em>) to assess the transcriptome-level response to the disease. Compared to the previous bovine microarray-based study of brain gene expression in CWD-infected elk, our study has the opportunity to assess a broader range of transcripts while avoiding the detection issues associated with probes that reduce performance for identifying differentially expressed genes [10, 11]. The findings detailed here contribute to increasing our understanding of the molecular mechanisms underlying CWD-induced neurotoxicity in cervids.

Materials and methods

Deer brain samples

Deer brain tissue was obtained at necropsy from one uninfected and three clinically-affected WTD that had been orally infected with Wisc-1 prions [12]. Additional deer brain samples were obtained from hunter-harvested WTD (Wisconsin, CWD test negative, <i>n</i> = 3) and from a Saskatchewan white-tailed deer herd depopulated for CWD control (<i>n</i> = 4). One deer from Saskatchewan was test positive for CWD (NBSK23); the other three were test-negative. All CWD+ deer were positive in both the obex and the retropharyngeal lymph nodes. Brain tissue from all deer were removed within 2 h of death, bisected along the sagittal plane and frozen on dry ice. Brain tissue did not include the obex region of the medulla oblongata which was used for CWD testing. Brain hemispheres were homogenized to a powder under liquid nitrogen using a mortar and pestle, and the total brain powder was sampled for subsequent RNA-seq analysis. All the samples were from adult deer. The sex of some of those deer were unknown, so those were determined based on mapping of RNA-seq reads from those samples to the sequence of the bovine Y chromosome. The CWD status of deer was determined by the Wisconsin Department of Natural Resources or the Canadian Food Inspection Agency using immunochemical detection of CWD prions in the retropharyngeal lymph nodes and immunohistochemical staining of the obex region of the medulla oblongata.

Western blot analysis

Powdered brain tissue was homogenized in an Omni Bead Beadrupor (Omni International, Kennesaw Georgia) with cold sterile water (10% w/v). A subset of brain homogenates were digested with proteinase K (50 mg/ml) for 30 min at 37°C, boiled in Laemmli buffer for 10 min, fractionated on 12% NuPAGE Bis-tris gels (Invitrogen) and transferred to PVDF membrane (Millipore). Membranes were blocked in 0.1% TBS-T / 5% milk for 1 h at room temperature. Incubation with the primary antibody, Bar224 1:10,000 (Cayman Chemical), was performed overnight at 4°C. Anti-mouse IgG alkaline phosphatase conjugated secondary antibody (Promega) was used at 1:10,000 with a fluorescent substrate (Attophos Promega).

RNA purification, library preparation and sequencing

Total RNA was isolated from powdered brain tissue using a commercial kit, following the manufacturer’s instructions (RNeasy Mini, Qiagen). RNA quality was assessed via spectrophotometry (NanoDrop Technologies, Inc.) and gel electrophoresis (Bioanalyzer 2100, Agilent Technologies). Library construction and sequencing were performed by the Centre d’Expertise et de Services of Génome Québec. Libraries were generated from 250 ng of total RNA. Messenger RNA enrichment was performed using the NEBNext Poly(A) Magnetic Isolation Module (New England BioLabs). cDNA synthesis was achieved with the NEBNext RNA First Strand Synthesis and NEBNext Ultra Directional RNA Second Strand Synthesis Modules (New England BioLabs). The remaining steps of library preparation were completed using the NEBNext Ultra II DNA Library Prep Kit for Illumina (New England BioLabs). Libraries then underwent 2x100bp sequencing using an Illumina HiSeq2500 platform. Sequencing data have been deposited into NCBI, accession number PRJNA756812.

Sequence read alignment to reference genomes

Following sequencing, raw reads were inspected for quality using FastQC v0.11.9 [13] and MultiQC [14]. Trimmomatic v0.39 [15] was used to remove poor quality (q < 33) and short (<36 nt) reads. The latest versions of the WTD reference genome assembly (Ovir.te.1.0) and its associated gene annotation file were downloaded from NCBI (GenBank assembly accession: GCF_002102435.1).
Prior to analysis, 25 rows in the GTF annotation file with an empty ‘gene_id’ attribute field and with gbkey “tRNA” were removed. The STAR short read aligner v2.7.3a [16] was used to index the reference genome and for subsequent alignment of the filtered read set. Mapping results were obtained in BAM format, sorted using samtools v1.7.0 [17] and used as input for featureCounts v2.0.0 [18] to count the number of alignments that overlapped exonic regions on both the sense and antisense strands, separately. Gene count matrices were exported for downstream analyses in R v3.6.1 [19].

Sequence reads were also matched to the most recent bovine reference genome assembly (ARS-UCD1.2; Ensembl Release 100, April 2020) with the expectation that the more complete genome sequence and annotations could provide additional insights into gene expression changes, using the read mapping and counting strategy as described above. To determine/verify the sex of the deer, the reads that remained unmapped after the initial alignment to the bovine reference genome (lacking the Y chromosome) were mapped to a separate bovine Y chromosome sequence (NCBI GenBank ID: CM011803.1) using STAR aligner and the counts of reads assigned to gene features on the Y chromosome were determined using featureCounts. Similar approaches have been used previously [20]. The ratio of the total reads that remained unmapped to any gene features on the bovine Y chromosome over the total reads (assigned and unassigned) based on the featureCounts summary report was then calculated. The distribution of those ratios were bimodal with known female deer having a ratio below 0.04 and known male deer having a ratio above 0.08. A Welch two-sample t-test to test for difference between means of the 2 groups indicated a highly significant difference (p-value was 1.922e-15), with the mean of the female group at 0.0293 (SD 0.0022) and the male at 0.0857 (SD 0.0024)). Sex determined by sequencing was 100% accurate with those deer of known sex.

Data exploration and differential gene expression

The steps followed for downstream analysis were identical for read counts generated from read mapping to WTD as well as to bovine genome reference sequences. Prior to downstream analysis, genes with low or inconsistent read depth (less than 15 reads in total across all samples, and/or less than 10 reads mapped per sample) were filtered out. A power analysis conducted using RNASeqPower version 1.26.0 [21] showed that with our relatively modest sample sizes, gene expression fold changes of 1.75 could be reliably detected at a power of 0.8 and a fixed false discovery rate (FDR) of 0.05. Normalized gene counts were fitted to a generalized linear model to identify differentially expressed genes (DEGs) according to CWD status. The model also accounted for variability arising between sequencing batches. Data was normalized using the trimmed mean of M-values procedure implemented in edgeR to account for technical variation between samples [22], and DEGs were identified using the thresholds outlined above. The preclinical sample (NBSK23) was not included in the differential expression analysis, maximizing the contrast between infected and healthy samples.

Enrichment analysis of differentially expressed genes

Functional enrichment analysis was performed using DAVID v6.8 to identify Gene Ontology (GO) terms (Biological Processes, Molecular Functions, Cellular Components) over-represented in the DEGs against a population set consisting of all genes identified as expressed [23, 24]. Only terms containing at least 5 DEGs were deemed enriched in our dataset at a threshold of FDR-adjusted P < 0.05. DEGs from the bovine reference genome mapping study were used as DAVID knowledgebase does not have GO mappings to WTD gene IDs, and the bovine genome is better annotated.

Quantitative real-time PCR validation

Total RNA from WTD brain tissues was used for quantitative real-time PCR (qRT-PCR). RNA from the three CWD positive deer, four CWD negative deer, and one preclinical CWD positive deer was reverse transcribed to cDNA using TaqMan Reverse Transcription Reagents (Applied Biosystems). A CFX96 Real-Time instrument (Bio-Rad) and iTaq Universal SYBR Green Supermix (Bio-Rad) were used following the manufacturer’s instructions. PCR primers were designed using Primer Blast [25]. PCR Primers (Supplementary Table 1, Additional File 1) either spanned introns or included an exon junction. The annealing temperature was 58°C for all reactions. Pooled cDNA prepared from white-tailed deer lymph nodes and brain was used to optimize primers and to produce standard curves. A reaction without template was used as a negative control for each target. The relative cDNA levels were calculated using the 2^(-ΔΔCt) method, with β-actin used as the reference gene for normalization as previously described [26, 27]. A two-sample t-test with unequal variance was performed on the data for each target. The back-transformed ratios (2^-ΔΔCt), along with 95% CI and p-values, are reported. To assess evidence for any overall difference between the positive and negative groups across all target genes, a linear mixed model was fitted with fixed effects for target and the group/target interaction and a random effect for sample, where the group/target interaction is the term that assesses differences between the groups across the targets.
Investigation of the neural bacteriome using Kraken2

Reads that failed alignment to the Ovir.te.1.0 genome were mapped to a database comprising the entire collection of complete bacterial genomes deposited in NCBI using Kraken2 (v.2.1.1) [28] (database created in Dec. 2020), to assign taxonomic tags to all recovered bacterial sequences. Following read mapping, genomes represented by <2 reads across all samples were removed. DeSeq2 was used to identify differentially detected bacteria (FDR < 0.05) according to disease status. Sequencing batch effects were included in the generalized linear model. All plots depicting microbial data were prepared in R using base R packages and ggplot2.

Results

PrP\textsuperscript{CWD} abundance in the brains of white-tailed deer

Differential gene expression induced by CWD will be affected by the stage of prion infection as determined by prion neuroinvasion and accumulation in the central nervous system. The three clinically affected deer had high levels of proteinase-K resistant PrP isoforms (PrP\textsuperscript{CWD}) in their brains as determined by western blot (Fig. 1). One deer (NBSK23) was culled at a preclinical time point and possessed a lower abundance of PrP\textsuperscript{CWD}. The time post-infection is unknown.

Characteristics of RNA-Seq data

RNA used for sequencing library prep was of high quality (RIN > 7), even in the hunter harvest samples. RNA sequencing generated an average of 46.5 ± 7.05 million reads per sample. Descriptive details of samples, sequencing data and mapping characteristics are provided in Table 1. Of interest, the preclinical animal (NBSK23) did not cluster closely with the clinically infected deer in either the PCA plot (Fig. 2) or the hierarchical clustering (Supplementary Fig. 1, Additional File 1). Greater interanimal variation in gene expression profiles was evident among CWD affected deer than the healthy cohort. The sequencing data, in general, differed according to batch in terms of alignment rate. On average, the total number of sequencing reads in batch one was 22% higher than from batch two.

Identification of differentially expressed genes

Differential gene expression analysis using edgeR identified 255 genes that were significantly affected by CWD infection when mapped to the WTD genome assembly. 197 genes were upregulated in clinically affected CWD\textsuperscript{+} deer. A subsequent analysis using mapping to the bovine reference assembly identified 229 DEGs, with 186 of these upregulated in the clinically infected animals (Additional File 2). There was significant overlap between the sets of DEGs identified by mapping to either the WTD or bovine genome (Fig. 3). 140 upregulated genes and 19 downregulated genes were common to both datasets. Unannotated genes (denoted with “LOC” symbol preceding NCBI’s Entrez GeneID) comprised 27.05% of the DEGs identified using the WTD reference assembly. In contrast, just 6.68% of the bovine DEGs lacked an Ensembl annotation (denoted “NA”).

![Western blot analysis of prion protein from deer brain samples used for transcriptional profiling. Powdered brain tissue was homogenized to 10% w/v in water and analyzed by Western blotting using the monoclonal antibody Bar224 at a dilution of 1:10,000. Prion proteins were examined with and without proteinase K treatment. The NBSK23 sample is from a preclinical infection. Standardized amounts of brain homogenate based on volume were loaded in each lane.](Fig. 1)
Functional enrichment of differentially expressed genes

Enrichment analysis was performed for the DEGs identified using the bovine reference genome, as the bovine gene annotations (Ensembl gene IDs used) allowed for more complete GO term assignment (terms were assigned for 186 upregulated and 34 downregulated DEGs). Eighteen GO terms (7 Biological Processes, 7 Cellular Component, 4 Molecular Function) were overrepresented among the upregulated genes (adj. \( P < 0.05\), Fig. 4, Table 2). The Biological Processes enriched in CWD+ brain tissue included GO:0006954 – inflammatory response, GO:0045087 – innate immune response,
GO:0007229 – integrin-mediated signaling pathway and GO:0045087 – Phagosome. Molecular Functions enriched among the DEGs detected in CWD+ brain tissue included GO:00004497 – monooxygenase activity, GO:0005506 iron ion binding, and GO:0005178 – integrin binding. No enriched terms were identified among the downregulated DEGs.

**Validation of gene expression profiles**

Quantitative real-time PCR was used to further evaluate fourteen DEGs identified by the RNA-seq analysis. Consistent with the RNA-seq results, we found that MYOC and SCN2D were downregulated and that ABCC3, C5AR1, CD14, CD68, CD163, EMP1, GPNMB, ITGB2, ITGB3, LCP1, RGS1, TREM2 were upregulated. The relative expression levels of each gene are presented in Fig. 5. A mixed model analysis showed statistically significant evidence for overall differences between the infected and uninfected deer across all target genes; the group/target interaction was statistically significant, with $p < 0.0001$. At the level of individual genes, statistical power was limited by the sample number and the variation, especially in the CWD+ samples. Unadjusted $p$-values calculated using student’s t-test are reported for each gene.

**Bacterial sequence provenance in deer brain tissue**

An alternative hypothesis to the prion hypothesis suggests that CWD is the result of a Spiroplasma infection [29]. We tested this hypothesis by analyzing our sequencing data to assess the taxonomic provenance of bacterial sequences recovered, and investigating whether this microbial community had a signature related to CWD status. We reasoned that if spiroplasma bacteria contributed to CWD pathogenesis, then we should be able to detect these transcripts in a CWD specific manner. We mined our data, by aligning the non-deer reads to a database of complete bacterial genomes, to determine the nature, if any, of bacterial expression in the neural tissues of deer. Approximately 17,000 non-deer reads per sample were aligned to a database of complete bacterial genomes using Kraken2, which mapped to 463 non-singleton bacterial species. Principal component analysis did not separate the data according to disease status (Fig. 6). These data do not support a hypothesized bacterial etiology for CWD. Rather, the sequencing batch was the major determinant of differences in the reads mapped to microbial communities (Fig. 6, Supplementary Fig. 2, Additional File 1). The most abundant reads that mapped to the bacterial database were to transcripts from *Staphylococcus*.
haemolyticus, which contributed, on average, 10.8% of all bacterial-mapped reads per sample. Other bacterial-mapped reads aligned with transcripts from Oceanobacillus iheyensis, Streptomyces lavendulae, and Escherichia coli. Less than 0.00008% of the reads mapped to genes from Spiroplasma species, about 38 reads. Differential abundance analysis of bacterial-mapped reads detected using DeSeq2 did not reveal any significantly different abundance between clinical and healthy animals (FDR > 0.05), in a model that included sequencing batch, and excluded the subclinical animal.

**Discussion**

In the face of ecological, economical and, potentially, public health risks of CWD, it is important to gain further understanding of disease pathogenesis on a molecular scale. Transcriptional regulation is a primary mechanism underpinning disease progression [30], but the limited data published on CWD-infected cervids has employed microarray analysis of lymphatic and neural elk tissues [8] and RNA-seq of lymphatic and hepatic samples collected from infected deer [9]. Comparative transcriptomic analysis of prion disease responses between mice and rats identified shared neuroinflammatory responses, however, at the level of individual genes homologous responses were not conserved and many genes deregulated by prion infection in mice were unaffected in rats [31]. The present study provides a comprehensive profile of gene-expression changes in response to CWD in the brain of CWD-infected deer. We evaluated differences between clinically affected and healthy white-tailed deer using bulk RNA-seq, assessing changes in the neural transcriptome of infected animals to define the molecular pathology of this universally fatal disease.

Consistent with observations in rodent prion diseases [31, 32] and neurodegenerative diseases with comparable pathology in humans [33], our data confirm the up-regulation of neuroinflammatory responses observed in many prion diseases. Several ontologies related to inflammation were enriched among the upregulated genes, with multiple genes related to innate and complement immune activation showing upregulation in the diseased
deer. Prion diseases are characterized by the early onset of gliosis in the brain of the infected animal with microglial and astrocyte proliferation occurring simultaneously with the accumulation of prion aggregates [34], and often prior to neuronal loss, spongiform change, and clinical signs. The expression levels of genes involved in microglia activation were higher in CWD+ animals. Microglia are the resident macrophages of the CNS, playing a key role in the maintenance of homeostasis via surveillance and phagocytosis in the brain. Survival and proliferation of microglia relies on signaling via the colony stimulating factor 1 receptor (CSF1R) [35], whose gene was upregulated in the CWD+ deer. In mouse prion disease, CSF1R increases microglial activation and promotes

Table 2 Gene ontology pathway terms enriched among the DEG

| Term                                                   | DEG (%) | Fold Enrichment | P-value |
|--------------------------------------------------------|---------|-----------------|---------|
| **Biological Process**                                  |         |                 |         |
| GO:0006954 inflammatory response                        | 8.6     | 8.2             | <0.001  |
| GO:0007155 cell adhesion                                | 7.4     | 6.5             | <0.001  |
| GO:0045087 innate immune response                       | 6.9     | 6.2             | 0.001   |
| GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway | 4.0     | 10.0            | 0.011   |
| GO:0019370 leukotriene biosynthetic process             | 2.3     | 41.0            | 0.015   |
| GO:0007229 integrin-mediated signaling pathway          | 4.0     | 9.0             | 0.016   |
| GO:007374 positive regulation of ERK1 and ERK2 cascade  | 4.6     | 6.0             | 0.042   |
| **Cellular Component**                                  |         |                 |         |
| GO:0005887 integral component of plasma membrane        | 14.0    | 3.1             | <0.001  |
| GO:0009986 cell surface                                 | 8.0     | 3.9             | 0.004   |
| GO:0016324 apical plasma membrane                       | 5.7     | 5.7             | 0.003   |
| GO:0045121 membrane raft                                | 5.1     | 6.5             | 0.003   |
| GO:0005576 extracellular region                         | 7.4     | 3.9             | 0.003   |
| GO:0005615 extracellular space                          | 11.0    | 2.4             | 0.019   |
| GO:0016021 integral component of membrane               | 30.0    | 1.5             | 0.017   |
| **Molecular Function**                                  |         |                 |         |
| GO:0004997 monooxygenase activity                       | 2.9     | 18.0            | 0.034   |
| GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 2.9     | 18.0            | 0.034   |
| GO:0005506 iron ion binding                             | 4.6     | 6.4             | 0.027   |
| GO:0005178 integrin binding                             | 2.9     | 13.0            | 0.035   |

1The number of DEG present in the list of upregulated genes as a percentage of the total number of genes involved in each respective term or pathway. 2P-values are Holm–Bonferroni corrected.

Fig. 5 Fourteen genes de-regulated by CWD were validated by RT-qPCR. Relative gene expression levels for each gene are presented for the CWD positive (red), CWD negative (green) and preclinical (blue) groups. A relative gene expression method (2 ΔΔCt) was used to normalize and compare the data from each group. The error bars show the mean +/- SE.
neurodegeneration [36]. CSF1R upregulation by CWD in white-tailed deer is indicative of microglial activation. The upregulation of the CXCR4 gene in the CWD+ animals supports microglial activation. CXCR4 is a chemokine receptor with broad modulatory functions in immune system regulation, that also regulates apoptosis and neuronal guidance through astroglial signaling and microglial activation [37]. A recent meta-analysis found that upregulation of this gene was a common pathology of multiple human neurodegenerative diseases, perhaps indicative of conserved processes underpinning these and prion diseases [37, 38].

Further evidence of microglia proliferation was seen in upregulation of complement receptor genes. The complement system is an essential component of innate immunity, important in protecting from infection and repairing tissue damage [39]. Activation of complement also contributes to the neuroinflammation and tissue damage accompanying traumatic brain injury [40], and a role(s) for complement has been demonstrated in human cases

![Fig. 6 Lack of bacterial signature in CWD affected deer. Principal component analysis plots showing the samples of neural tissue according to (A) disease status and (B) sequencing batch generated using Kraken2 following alignment of all non-deer reads to a reference database comprising all completed NCBI bacterial genomes.](image)
of prion [41], Alzheimer’s, and Huntington’s diseases [42]. Complement activation fragments, C3a and C5a, interact with cellular receptors to recruit and activate microglia and clear pathogens [43]. Genes encoding both known C5a receptors (CSAR1 and CSAR2) were upregulated in our dataset, indicating neural complement activation accompanies CWD in deer.

Both protective (M1) and neurotoxic (M2) phenotypes of microglial activation in prion diseases have been proposed [44]. Inhibiting microglial activation increased survival time and delayed the onset of clinical symptoms in rodent prion diseases [36], but complete absence of microglia accelerated death in prion-infected mice [45]. The role of microglial activation in prion disease changes with advancing illness, from phagocytosing infectious prions during early infection, to the promotion of inflammation leading to further degeneration in clinical disease. A strong relationship between the expression of immune-related genes and CWD diagnosis has been reported in the retropharyngeal lymph nodes of white-tailed deer [9], and in Rocky Mountain elk [8].

Dysregulation of calcium binding / signaling pathways is thought to be contributory to prion-induced cell death, and was associated with CWD in deer and elk [8, 9]. The three most upregulated genes in our dataset encoded the A8, A9, & A12 family members of the S100 protein family (Additional file 2). This multifunctional family of calcium-binding proteins have been implicated in Alzheimer’s disease (AD) pathogenesis, and are upregulated in cases of traumatic brain injury, natural aging, and neuronal damage [46]. Elevated levels of S100 proteins can be used as a clinical biomarker for CJD diagnosis in humans [47], and these proteins were also enriched in a murine model of scrapie [48], indicating a conserved role in TSEs across species. Many neurodegenerative diseases are accompanied by a similar pattern of chronic neuroinflammation, contributing to tissue degeneration. S100A8 and S100A9 heterodimerize to form calprotectin in vivo, and their expression is modulated by pro-inflammatory cytokine expression as part of the innate immune response to protein aggregation in the brain. This heterodimer is upregulated in microglial cells that collocate with amyloid plaques in the brain during AD. S100A9 in particular is implicated in neurodegeneration, with its intranasal application inducing cellular stresses in the brain as well as impairing learning ability [9].

While prions are accepted as the causative agents of TSEs, there is a hypothesis that Spiroplasma spp. in lymphatic or neural tissues may be the etiological agent responsible for the transmissible spongiform encephalopathies [29]. As such we took a metagenomic approach to investigate if there is a microbial community in the brains of deer and in particular, one that is specific to CWD+ deer. Of the ~46 million RNA-seq reads generated per sample, only ~0.04% of them could be assigned to a bacterium by Kraken2. The most likely explanations for the mapping of reads from a deer brain sample to bacterial genomes are contamination of the sample by commensal bacteria, chance misassignment of unannotated deer transcripts to any of the bacterial genomes deposited in NCBI, or contamination of molecular biology reagents used to prepare the RNAseq libraries. We see examples of all of these in the RNAseq bacterial assignments. Both Staphylococcus haemolyticus and Escherichia coli are common flora of mammals. The presence of reads from Oceanobacillus iheyensis is extremely unlikely as this bacterium is a halotolerant bacillus from deep sea sediment [49]. Contamination of RNAseq datasets by Streptomyces reads has previously been described [50] and Streptomyces lavendulae, in particular, is used for biopharmaceutical production. While we did see evidence of bacterial transcripts in the RNAseq data, there was no bacterial signal that correlated with disease status. Less than 0.00008% of the reads mapped to genes from Spiroplasma species, about 38 reads. These data do not corroborate the hypothesized role of Spiroplasma or any other bacteria in the etiology of CWD and support previous data refuting the hypothesis [51, 52].

RNAseq analysis of the preclinical case, NBSK23, was indeterminate and it did not cluster with the clinical samples. While the deer was positive for CWD in both the retropharyngeal lymph node and obex, the abundance of PrPCWD in the whole brain sample was substantially lower than in the clinical deer samples. As prion infections all have a relatively long preclinical period when infectious prions accumulate in the absence of clinical signs, it is prion accumulation in this deer was insufficient to elicit measurable neurodegenerative and neuro-inflammatory changes.

This study presents the first comprehensive transcriptome analysis of CWD in the brain tissue CWD-positive cervids. In our studies, we observed inter-animal variation between CWD+ animals in both RNASeq and qPCR data, indicative of a non-uniform response to disease. Our deer samples were collected from different cohorts of wild deer and included experimentally infected animals as well as hunter-harvested and captive deer. This stands in contrast to the majority of data in the literature concerning neural transcriptional responses to prion diseases that use cohorts of inbred mice. One deer samples, 1285, had a prion protein polymorphism (wt/96) known to slow CWD progression. Deer with the wt/96 genotype survived 38% longer than deer carrying two wild-type alleles [12]. Our sample size was limited by the difficulty of carrying out long-term experiments in captive cervids under biosecure conditions.
Summary & Conclusions
This study examined the transcriptional response of the brain to CWD infection in white-tailed deer. We demonstrated the large-scale neuroinflammation that accompanies CWD infection is underpinned by activation of both microglia and the complement system. The gene expression changes highlight the role of innate immunity in prion infection providing for disease biomarkers and for potential targets for therapeutic agents. Finally, we mined our data to address the speculative hypothesis that specific bacteria are the etiological agent of CWD, but found no evidence to support this hypothesis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12864-022-08306-0.

Acknowledgements
The authors are grateful for the provision of samples by the Canadian Food Inspection Agency. We also thank the platform personnel at the Centre d'expertise et de services Génomique Québec for their expertise in performing RNA-sequencing. We thank Dr. Aaron Rendahl for Statistical analysis support, and Kristelle Mendoza and Emma Baker for assistance with qRT-PCR. This research was enabled with computing support provided by WestGrid (http://www.westgrid.ca), Compute Canada (http://www.computecanada.ca) and Cybera (https://www.cybera.ca).

Authors' contributions
AH, JMA, DM, and PS (UofA) conceived and designed the study. AH performed the wet lab work and collected the tissue samples. NG and PS (UMN) performed the qPCR validation. ECH and AK performed all bioinformatic and statistical analyses of sequencing data. All authors wrote, reviewed and approved the final manuscript.

Funding
This work was performed as part of the Systems Biology and Molecular Ecology of Chronic Wasting Disease project that was funded by Genome Canada, Genome Alberta, the Alberta Prion Research Institute, Alberta Agriculture and Forestry and the University of Alberta. This work was also partially funded by the Minnesota Environment and Natural Resources Trust Fund as recommended by the Legislative-Citizen Commission on Minnesota Resources (LCCMR); the Trust Fund is a permanent fund constitutionally established by the citizens of Minnesota to assist in the protection, conservation, preservation, and enhancement of the state’s air, water, land, fish, wildlife, and other natural resources.

Availability of data and materials
The datasets generated and/or analysed are available in the [National Center for Biotechnology Information BioProject] repository, accession number PRJNA756812, (www.ncbi.nlm.nih.gov/bioproject/PRJNA756812).

Declarations
Ethics approval and consent to participate
No animals were used in this research. Deer tissues were banked, provided with permission by hunters or the Canada Food Inspection Agency. Original ethics approval for the experimental deer samples was provided by the School of Veterinary Medicine, Animal Care and Use Committee at the University of Wisconsin, as described [12].

Consent for publication
All authors consent to the publication.

Competing interests
Paul Stothard is an Associate Editor of BMC Genomics.

Author details
1 Department of Agricultural, Food and Nutritional Science, University of Alberta, 2-51 General Services Bldg, Edmonton, AB T6G 2H1, Canada. 2 Leithbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta, Canada. 3 Lacombe Research and Development Centre, Agriculture and Agri-Food Canada, Lacombe, Alberta, Canada. 4 Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada. 5 Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, USA.

Received: 20 September 2021   Accepted: 22 December 2021
Published online: 21 January 2022

References
1. Williams ES. Chronic wasting disease. Vet Pathol. 2005;42(5):530–49.
2. Haley NJ, Hoover EA. Chronic wasting disease of cervids: current knowledge and future prospects. Ann Rev Anim Biosci. 2015;3:305–25.
3. Edmunds DR, Kauffman MJ, Schumaker BA, Lindzey FG, Cook WE, Kreeger TJ, et al. Chronic wasting disease drives population decline of white-tailed deer. PLoS One. 2016;11(8):e0161127.
4. Chesebro B. Introduction to the transmissible spongiform encephalopaties or prion diseases. Br Med Bull. 2003;66:1–20.
5. Otero A, Duque Velasquez C, Johnson C, Herbst A, Bolea R, Badiola JJ, et al. Prion protein polymorphisms associated with reduced CWD susceptibility limit peripheral PrP(CWD) deposition in orally infected white-tailed deer. BMC Vet Res. 2019;15(1):50.
6. Rivera NA, Brandt AL, Novakofski JE, Mateus-Piñella NE. Chronic wasting disease in Cervids: prevalence, Impact And Management Strategies. Vet Med (Auckl). 2019;10:123–39.
7. Barbisín M, Vanni S, Schmadicke AC, Montag J, Motzkus D, Optitz L, et al. Gene expression profiling of brains from bovine spongiform encephalopathy (BSE)-infected cynomolgus macaques. BMC Genomics. 2014;15:434.
8. Busu U, Almeida LM, Dudás S, Graham CE, Czub S, Moore SS, et al. Gene expression alterations in Rocky Mountain elk infected with chronic wasting disease. Prion. 2012;6(3):282–301.
9. Trone-Launer EK, Wang J, Lu G, Mateus-Piñella NE, Zick PR, Lamer JT, et al. Differential gene expression in chronic wasting disease-positive white-tailed deer (Odocoileus virginianus). Ecol Evol. 2019;9(22):12600–12.
10. Zhao S, Fung-Leung WP, Bittner A, Nigo K, Liu X. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS One. 2014;9(1):e86444.
11. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.
12. Johnson CJ, Herbst A, Duque-Velasquez C, Vanderloo JP, Bochser PL, Chappell R, et al. Prion protein polymorphisms affect chronic wasting disease progression. PLoS One. 2011;6(3):e17450.
13. de Sena BG, Smith AD. Falco: High-speed FastQC emulation for quality control of sequencing data. F1000Research. 2019;8:1874.
14. Evelis P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047–8.
15. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20.
16. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast and memory-efficient RNA-seq alignment. Bioinformatics. 2013;29(1):15–21.
17. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078–9.
18. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923–30.
19. R Core Team: R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019.
20. Teixeira SA, Ibelli AMG, Cantão ME, Oliveira HC, Ledur MC, Peixoto JO, et al. Sex determination using RNA-sequence analyses in early prenatal pig development. Genes. 2019;10(12).
21. Hart SN, Therneau TM, Zhang Y, Poland GA, Kocher JP. Calculating sample size estimates for RNA sequencing data. J Comput Biol. 2013;20(1):970–8.
22. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(11):139–40.
23. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
24. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(11):1–13.
25. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012;13:134.
26. Ganger MT, Dietz GD, Ewing SJ. A common base method for analysis of qPCR data and the application of simple blocking in qPCR experiments. BMC Bioinformatics. 2017;18(1):534.
27. Lengacher S, Magistretti PJ, Pellello L. Quantitative rt-PCR analysis of uncoupling protein isoforms in mouse brain cortex: methodological optimization and comparison of expression with brown adipose tissue and skeletal muscle. J Cereb Blood Flow Metab. 2004;24(7):780–8.
28. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with kraken. J Genome Biol. 2019;20(1):257.
29. Bastian FO. The case for involvement of spiroplasma in the pathogenesis of transmissible spongiform encephalopathies. J Neuropathol Exp Neurol. 2014;73(2):104–14.
30. Kim TK, Lee I, Cho JH, Canine B, Keller A, Price ND, et al. Core transcriptional regulatory circuits in prion diseases. Mol Brain. 2020;13(1):10.
31. Herbst A, Ness A, Johnson CJ, McKenzie D, Aiken JM. Transcriptomic analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
32. Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, Petritis B, et al. A systems approach to prion disease. Mol Syst Biol. 2009;5:252.
33. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2017;35(11):1265–75.
34. Chen YJ, Olschowka JA, OBanion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.
35. At BMC, research is always in progress. Learn more: biomedcentral.com/submissions
36. Bastian FO. The case for involvement of spiroplasma in the pathogenesis of transmissible spongiform encephalopathies. J Neuropathol Exp Neurol. 2014;73(2):104–14.
37. Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol. 2007;44(5):999–1010.
38. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007;25(11):1265–75.
39. Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, Irvine KM. Immune response to neuroinflammation. Mol Neurodegener. 2018;3(1):5.
40. Chen YJ, Olschowka JA, OBanion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.
41. Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, Irvine KM. Immune response to neuroinflammation. Mol Neurodegener. 2018;3(1):5.
42. Bastian FO. The case for involvement of spiroplasma in the pathogenesis of transmissible spongiform encephalopathies. J Neuropathol Exp Neurol. 2014;73(2):104–14.
43. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2017;35(11):1265–75.
44. Chen YJ, Olschowka JA, OBanion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.
45. Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, Irvine KM. Immune response to neuroinflammation. Mol Neurodegener. 2018;3(1):5.
46. Bastian FO. The case for involvement of spiroplasma in the pathogenesis of transmissible spongiform encephalopathies. J Neuropathol Exp Neurol. 2014;73(2):104–14.
47. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2017;35(11):1265–75.
48. Chen YJ, Olschowka JA, OBanion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.
49. Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, Irvine KM. Immune response to neuroinflammation. Mol Neurodegener. 2018;3(1):5.
50. Bastian FO. The case for involvement of spiroplasma in the pathogenesis of transmissible spongiform encephalopathies. J Neuropathol Exp Neurol. 2014;73(2):104–14.
51. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2017;35(11):1265–75.
52. Chen YJ, Olschowka JA, OBanion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.
53. Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, Irvine KM. Immune response to neuroinflammation. Mol Neurodegener. 2018;3(1):5.
54. Bastian FO. The case for involvement of spiroplasma in the pathogenesis of transmissible spongiform encephalopathies. J Neuropathol Exp Neurol. 2014;73(2):104–14.
55. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2017;35(11):1265–75.
56. Chen YJ, Olschowka JA, OBanion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.
57. Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, Irvine KM. Immune response to neuroinflammation. Mol Neurodegener. 2018;3(1):5.
58. Bastian FO. The case for involvement of spiroplasma in the pathogenesis of transmissible spongiform encephalopathies. J Neuropathol Exp Neurol. 2014;73(2):104–14.
59. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2017;35(11):1265–75.
60. Chen YJ, Olschowka JA, OBanion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.
61. Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, Irvine KM. Immune response to neuroinflammation. Mol Neurodegener. 2018;3(1):5.